Erleada (apalutamide) is usually taken until cancer progresses past a certain point or you start to have unacceptable side effects.

• In the SPARTAN clinical trial (NCT01946204) using apalutamide for men with castration-resistant metastasis-free prostate cancer, some patients were still using apalutamide at 36 months.
• In the TITAN clinical trial (NCT02489318) studying men using apalutamide for metastatic, castration-sensitive prostate cancer, some patients were still taking it after 2 years.

Erleada is an androgen blocker.

• Androgens, such as testosterone, can help prostate cancer growth.
• As Erleada blocks androgens effect on the tumor, it makes it harder for the tumor to advance.
• This means patients taking Erleada have a longer overall survival and have a longer time before their disease progresses.